Mingyuan Du
Papers
1
Total Citations
4
H-Index
1
About
Mingyuan Du is a leading clinical researcher in head and neck oncology, with a primary focus on human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Their most impactful work centers on pioneering neoadjuvant immunotherapy strategies to improve outcomes and reduce treatment morbidity. Du’s landmark phase 2 trial, published in 2025, investigated the combination of sintilimab (an anti-PD-1 inhibitor) with cisplatin and nab-paclitaxel chemotherapy prior to transoral robotic surgery (TORS) for resectable HPV-positive OPSCC. This study demonstrated a major pathological response rate as the primary endpoint, showcasing a promising approach to de-escalate treatment while maintaining oncologic control. With 4 citations already for this recent work, Du’s contributions are gaining rapid recognition in the field. Their research bridges the gap between immunotherapy and minimally invasive surgery, offering a potential new standard for organ preservation and functional outcomes. Du’s work is particularly notable for its direct clinical applicability, addressing the critical need for effective, less toxic regimens in HPV-driven cancers. As a rising authority, Du continues to shape the future of precision oncology in head and neck cancer.
Research Focus
Key Achievements
Top Papers
- 1